Madrid, Spain: CBD treatment is neuroprotective and is associated with improved memory in preclinical models of Alzheimer’s disease (AD), according to data published in the journal Alzheimer’s Research and Therapy.
Spanish researchers assessed the impact of CBD in in vitro and in vivo models of AD. They reported that CBD reduces neuroinflammation, reduces the build-up of proteins associated with the onset of AD, significantly improves long-term and short-term spatial memory, and promotes neuronal repair and regeneration.
“These multifaceted effects of CBD, ranging from molecular-level modulation to behavioral improvements, underscore its potential as a comprehensive therapeutic approach for AD,” the study’s authors concluded. “These data present CBD as a potential target to combat not only molecular deficits in AD but also cognitive impairment, offering a promising therapeutic approach that could potentially slow disease progression and improve quality of life for AD patients.”
Full text of the study, “Cannabidiol as a multifaceted therapeutic agent: Mitigating Alzheimer’s disease pathology and enhancing cognitive function,” appears in Alzheimer’s Research and Therapy. Additional information on cannabinoids and Alzheimer’s disease is available from NORML’s publication, Clinical Applications for Cannabis and Cannabinoids.